Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther. 2010;87:593–600.PubMedCrossRef 10. Hoever

P, Dorffner G, Beneš H, Penzel T, Danker-Hopfe H, Barbanoj MJ, et al. Orexin receptor antagonism, a new selleck products sleep-enabling paradigm: A proof-of-concept clinical trial. Clin Pharmacol Ther. 2012;91:975–85.PubMedCrossRef 11. Hoever P, de Haas SL, Dorffner G, Chiossi E, van Gerven JM, Dingemanse J. Orexin receptor antagonism: an ascending multiple-dose study with almorexant. J Psychopharmacol. 2012;26:1071–80.PubMedCrossRef 12. Hoch M, Hoever P, Zisowsky J, Priestley A, Fleet D, Dingemanse J. Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human

subjects. Pharmacology. 2012;89:53–7.PubMedCrossRef 13. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer selleck inhibitor V, Gan L, Grimm S, Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research U0126 datasheet (CDER), et al. The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos. 2003;31:815–32.PubMedCrossRef 14. Hoch M, Hoever P, Alessi F, Theodor R, Dingemanse J. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects. Eur J Clin Pharmacol. Methocarbamol 2013;69:523–32.PubMedCrossRef 15. Holford NH. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect

relationship. Clin Pharmacokinet. 1986;11:483–504.PubMedCrossRef 16. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73:67–74.PubMedCrossRef 17. Sullivan DM, Ford MA, Boyden TW. Grapefruit juice and the response to warfarin. Am J Health Syst Pharm. 1998;55:1581–3.PubMed 18. Mohammed Abdul MI, Jiang X, Williams KM, Day RO, Roufogalis BD, Liauw WS, et al. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol. 2008;154:1691–700.PubMedCrossRef 19. Ouellet D, Bramson C, Carvajal-Gonzalez S, Roman D, Randinitis E, Remmers A, et al. Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin. Br J Clin Pharmacol. 2006;61:741–5.PubMedCrossRef 20. Draft Guidance for Industry. Drug interaction studies—study design, data analysis, implications for dosing and labeling recommendations. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2012. 21. Malhotra B, Alvey C, Gong J, Li X, Duczynski G, Gandelman K. Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Br J Clin Pharmacol. 2011;72:257–62.PubMedCrossRef 22. Hoch M, Hoever P, Theodor R, Dingemanse J.